Burning Rock Biotech
Zhihong (Joe) Zhang serves as General Manager at Burning Rock Dx since October 2023 and has held the position of Chief Technology Officer at 燃石医学 Burning Rock Biotech since April 2016. Prior experience includes a tenure at Illumina from January 2008 to March 2016, where responsibilities included leadership in product development for Next Generation Sequencing and sample preparation applications, along with senior roles in TruSeq assay development and data analysis. Earlier roles include Research Associate at Howard Hughes Medical Institute and Senior Fellow at the University of Washington between 2005 and 2007. Zhihong (Joe) Zhang earned a Ph.D. in Molecular Genetics and Microbiology from Duke University, where studies were completed from 2000 to 2005, and holds an MS/BS in Biochemistry from Fudan University, completed in 2000.
This person is not in any teams
This person is not in any offices
Burning Rock Biotech
1 followers
Founded in 2014, Burning Rock Biotech is specialized in NGS (Next-Generation Sequencing) diagnositcs solutions for precision medicine in oncology. Thus far, Burning Rock has developed 32 products for different cancer types and clinical applications, ranging from companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. Burning Rock has established China’s first CLIA ((Clinical Laboratory Improvement Amendments)-certified NGS laboratory for both ctDNA and tumor tissue assays. Through deep collaborations with over 300 top provincial and national hospitals, the company has accumulated one of the largest cancer genomic databases in solid tumors in China. Besides providing NGS test services in an LDT model, Burning Rock also pioneers in providing one-stop NGS platform solutions and enabling high-quality NGS tests at hospitals’ pathology labs, which will benefit more patients in the long run. With the first NMPA (National Medical Products Administration)-approved NGS kit in China, strategic collaborations with Agilent, PerkinElmer, Illumina, Qiagen, and numerous pharmaceutical companies, Burning Rock is dedicated to developing innovative and reliable NGS diagnostics products to benefit cancer patients.